Meeting
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
Authors
Mo Yang
EMD Serono, Rockland, MA
Mo Yang , Joanna P. MacEwan , Sai Sriteja Boppudi , Monica McClain , Richard O'Hara Jr., Frank Liu , Paul K. Paik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9051)
DOI
10.1200/JCO.2023.41.16_suppl.9051
Abstract #
9051
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns in patients with stage IV non-small cell lung cancer (NSCLC) in U.S. community-based oncology practice setting.
First Author: Anthony Sireci
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
First Author: Makenzi Colleen Evangelist
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox